Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States

被引：0
|
作者：
Shujing Zhang
Arielle G. Bensimon
Ruifeng Xu
Ruixuan Jiang
Alexandra Greatsinger
Adina Zhang
Mizuho Fukunaga-Kalabis
Clemens Krepler
机构：
[1] Merck & Co.,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Adjuvant treatment; Cost-effectiveness analysis; Pembrolizumab; Stage IIB–IIC melanoma; US health sector perspective;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3038 / 3055
页数：17
相关论文
共 50 条
  • [41] A cost-effectiveness analysis of adjuvant treatment strategies for advanced-stage endometrial cancer
    Chura, J.
    Rocconi, R.
    Axtell, A.
    Straughn, J.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S78 - S78
  • [42] Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
    Schadendorf, Dirk
    Luke, Jason John
    Ascierto, Paolo A.
    Long, Georgina, V
    Rutkowski, Piotr
    Khattak, Adnan
    Del Vecchio, Michele
    de la Cruz-Merino, Luis
    Mackiewicz, Jacek
    Sileni, Vanna Chiarion
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    Dummer, Reinhard
    Carlino, Matteo S.
    Zhao, Yujie
    Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander
    Scolyer, Richard A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
  • [43] Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States
    Liu, Maobai
    Han, Sijie
    Zheng, Bin
    Cai, Hongfu
    Yang, Jing
    Zhuang, Qian
    Li, Na
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9483 - 9493
  • [44] COST EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) VERSUS IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA IN THE UNITED STATES
    Wang, J.
    Pellissier, J.
    Xu, R.
    Liu, F. X.
    Stevinson, K.
    Chmielowski, B.
    VALUE IN HEALTH, 2016, 19 (03) : A154 - A154
  • [45] Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States
    Hu, Jia
    Ye, Zhuomiao
    Xu, Zhe
    Hao, Zhinan
    Wang, Yongjun
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [46] Cost-effectiveness analysis of contraceptives available in United States
    Trussell, J.
    Lalla, A. M.
    Doan, Q., V
    Reyes, E.
    Pinto, L.
    Gricar, J. A.
    VALUE IN HEALTH, 2008, 11 (03) : A248 - A248
  • [47] Cost-effectiveness analysis of contraceptives available in the United States
    Trussell, J.
    Lalla, A.
    Pinto, L.
    Gricar, J.
    CONTRACEPTION, 2008, 78 (02) : 177 - 178
  • [48] COST-EFFECTIVENESS ANALYSIS OF ESKETAMINE IN TREATMENT-RESISTANT DEPRESSION IN THE UNITED STATES
    Hernandez, L. G.
    Li, S.
    Toro-Diaz, H.
    Zhang, Q.
    Sheehan, J.
    Le, H.
    VALUE IN HEALTH, 2019, 22 : S228 - S229
  • [49] Cost-effectiveness of adjuvant chemotherapy with uracil–tegafur for curatively resected stage III rectal cancer
    A Hisashige
    S Yoshida
    S Kodaira
    British Journal of Cancer, 2008, 99 : 1232 - 1238
  • [50] Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina
    Victoria Wurcel
    Emilie Scherrer
    Raquel Aguiar-Ibanez
    Juan Ignacio Altuna
    Fernando Carabajal
    Shrishti Jain
    Gargi Baluni
    Oncology and Therapy, 2021, 9 : 167 - 185
12345